Related Experiment Video

Updated: Jul 14, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines

C Ginestier1, J Adélaïde, A Gonçalvès

  • 1UMR599 Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, Marseille, France.

Oncogene
|May 26, 2007
PubMed

Insights

Sensitivity to trastuzumab, an anti-ERBB2 antibody treatment for breast cancer, is often linked to phosphorylated ERBB2 protein. This finding may help predict treatment response in patients with ERBB2-positive breast tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancers overexpressing the ERBB2 receptor tyrosine kinase are often treated with trastuzumab (Herceptin).
  • Resistance to trastuzumab is a significant clinical challenge, limiting its effectiveness in some patients.
  • Understanding the molecular mechanisms underlying trastuzumab resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the relationship between ERBB2 phosphorylation status and sensitivity to trastuzumab in breast cancer cell lines.
  • To identify potential biomarkers for predicting response to anti-ERBB2 targeted therapy.

Main Methods:

  • Screening of 18 diverse breast tumor cell lines for their response to trastuzumab.
  • Assessment of ERBB2 phosphorylation at tyrosine residue 1248 using specific antibodies.
  • Correlation analysis between trastuzumab sensitivity and ERBB2 phosphorylation levels.

Main Results:

  • A frequent association was observed between sensitivity to trastuzumab and the expression of phosphorylated ERBB2.
  • Specific phosphorylation of ERBB2 at tyrosine 1248 appears to be a key factor in determining cellular response to trastuzumab.
  • These findings suggest a potential mechanism for trastuzumab resistance or sensitivity.

Conclusions:

  • Phosphorylation status of ERBB2 is a critical determinant of trastuzumab efficacy in breast cancer.
  • Measuring ERBB2 phosphorylation may serve as a predictive biomarker for selecting patients who will benefit from trastuzumab therapy.
  • Further research into ERBB2 signaling pathways could lead to novel strategies to overcome trastuzumab resistance.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...